Hepatitis C, Chronic: Clinical Trials

201 trials for Hepatitis C, Chronic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

158 completed, 18 terminated, 14 unknown, 10 withdrawn. 201 Phase 3, 19 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3201Completed 158, Terminated 18, Unknown 14, Withdrawn 10, Active not recruiting 1
Phase 219Completed 13, Unknown 4, Terminated 1, Withdrawn 1

Follow Hepatitis C, Chronic: new trials by email Literature Review of Hepatitis C, Chronic trials Research Report on Hepatitis C, Chronic

Trials (filtered) newest first · largest first

All 201 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic
Phase 3Active not recruitingAtea Pharmaceuticals, Inc.8802025-06-022026-06-29
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients
Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c
Phase 3UnknownAssiut University502019-09-012019-09-12
SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C
SH229 tablets, Daclatasvir dihydrochloride - Hepatitis C, Chronic
Phase 2 / Phase 3UnknownNanjing Sanhome Pharmaceutical, Co., Ltd.4402019-03-292019-08-28
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
Elbasvir, Grazoprevir 50-100Mg Oral Tablet - Hepatitis C, Chronic
Phase 3CompletedKing Fahad Medical City302018-07-012020-11-20
A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie1002018-06-062020-03-17
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic
Phase 2 / Phase 3CompletedJohns Hopkins Bloomberg School of Public Health1502018-02-022021-05-18
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome
Phase 2 / Phase 3CompletedAin Shams University1002017-12-012018-09-20
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
Placebo, Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie5462017-10-042019-12-23
Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial
Administration of DAA-based treatment - Hepatocellular Carcinoma, Hepatitis C, Chronic
Phase 3UnknownAin Shams University802017-10-012018-06-11
Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie1602017-09-292019-11-21
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
glecaprevir (300mg)/pibrentasvir (120mg) - Hepatitis C, Chronic
Phase 3CompletedKirby Institute3802017-08-212019-12-11
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie2302017-08-072019-09-04
8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis
Zepatier Oral Product - Hepatitis C, Chronic
Phase 3CompletedKaohsiung Medical University Chung-Ho Memorial Hospital822017-06-122019-01-09
KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C
KW-136 capsule, Sofosbuvir - Hepatitis C, Chronic
Phase 3CompletedKawin Technology Share-holding Co., Ltd.3712017-06-072019-06-25
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie3432017-04-282020-07-13
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
Glecaprevir/pibrentasvir - Hepatitis C Virus (HCV)
Phase 3CompletedAbbVie1012017-03-282019-03-04
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation - Hepatitis C Virus (HCV)
Phase 2 / Phase 3CompletedAbbVie1292017-03-202023-05-09
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin - Hepatitis C Virus Infection
Phase 3CompletedAbbVie332016-11-212022-05-04
Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)
Ombitasvir/paritaprevir/ritonavir - Chronic Hepatitis C Virus
Phase 3WithdrawnAbbVie2016-09-012016-12-05
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Danoprevir, Ritonavir, peginterferon alfa-2a - Chronic Hepatitis C
Phase 3CompletedAscletis Pharmaceuticals Co., Ltd.1412016-06-012021-03-23

Showing 20 of 201. Sign in to see all of them.

Narrower conditions

Hepatitis C (93)  ·  Fibrosis (18)  ·  Hepatitis (11)  ·  Liver Cirrhosis (10)  ·  Liver Diseases (8)  ·  Acquired Immunodeficiency Syndrome (6)  ·  Infections (6)  ·  Virus Diseases (6)  ·  Hepatitis, Chronic (5)  ·  Carcinoma, Hepatocellular (4)  ·  Digestive System Diseases (4)  ·  Enterovirus Infections (4)  ·  Flaviviridae Infections (4)  ·  Hepatitis, Viral, Human (4)

Broader conditions

Blood-Borne Infections (201)  ·  Chronic Disease (201)  ·  Communicable Diseases (201)  ·  Disease Attributes (201)  ·  Pathologic Processes (201)  ·  Pathological Conditions, Signs and Symptoms (201)  ·  Digestive System Diseases (197)  ·  Flaviviridae Infections (197)  ·  Hepatitis, Viral, Human (197)  ·  RNA Virus Infections (197)  ·  Hepatitis, Chronic (196)  ·  Infections (195)  ·  Virus Diseases (195)  ·  Liver Diseases (193)  ·  Hepatitis (190)

Interventions

Ribavirin (122)  ·  peginterferon alfa-2a (51)  ·  peginterferon alfa-2b (39)  ·  ombitasvir (25)  ·  paritaprevir (22)  ·  dasabuvir (21)  ·  glecaprevir and pibrentasvir (21)  ·  Sofosbuvir (17)  ·  glecaprevir (17)  ·  pibrentasvir (16)  ·  N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (14)  ·  Viekira Pak (12)  ·  telaprevir (11)  ·  Simeprevir (8)  ·  ledipasvir, sofosbuvir drug combination (8)

Sponsors

AbbVie (39)  ·  Merck Sharp & Dohme LLC (33)  ·  Gilead Sciences (11)  ·  Hoffmann-La Roche (7)  ·  Tanabe Pharma Corporation (7)  ·  Boehringer Ingelheim (6)  ·  French National Agency for Research on AIDS and Viral Hepatitis (6)  ·  AbbVie (prior sponsor, Abbott) (5)  ·  Bausch Health Americas, Inc. (4)  ·  Janssen Pharmaceutical K.K. (4)  ·  Janssen-Cilag International NV (4)  ·  ANRS, Emerging Infectious Diseases (3)  ·  Debiopharm International SA (3)  ·  Foundation for Liver Research (3)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)

Countries

France (40)  ·  United States (40)  ·  Canada (32)  ·  Germany (32)  ·  Spain (32)  ·  United Kingdom (27)  ·  Puerto Rico (24)  ·  Australia (22)  ·  Italy (21)  ·  Belgium (19)  ·  Poland (19)  ·  Egypt (17)  ·  Japan (14)  ·  Russia (14)  ·  Taiwan (13)

Top investigators

Ralph T. Doyle (4)  ·  Eric Cohen, MD (3)  ·  Eric Bellissant, MD, PhD (2)  ·  Fumitaka Suzuki, MD (2)  ·  Gao Zhiliang, Doctor (2)

Results publications

PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 30529905, PMID 29377566, PMID 30868245, PMID 25040192, PMID 26947564, PMID 27553375, PMID 28193518, PMID 29404492, PMID 29461687, PMID 35174470, PMID 20189674, PMID 22626609, PMID 23607593, PMID 24126097, PMID 25196718, PMID 25583164, PMID 25777337, PMID 26173631, PMID 26321288, PMID 26936417, PMID 27920566, PMID 29180522, PMID 29909549, PMID 32682494, PMID 17311621, PMID 17573387, PMID 17894303, PMID 17894323, PMID 18167062, PMID 18237873, PMID 18848939, PMID 19052125, PMID 19291787, PMID 19445938, PMID 19625712, PMID 19676128, PMID 19747918, PMID 19766643, PMID 19852963, PMID 20070284, PMID 20211180, PMID 20362695, PMID 20512062, PMID 20564351, PMID 20600013, PMID 20600017

NIH funding

2014 (12), 2015 (11), 2016 (5), 2004 (3), 2005 (3), 2008 (2), 2009 (2), R01DA026727 (1), U01DK067767 (1)